Kilitch Drugs (India) Limited (KILITCH.NS)
INR 306.0
(-0.36%)
INR 306.0
(-0.36%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 643.88 Million INR | -6.6% |
| 2022 | 689.41 Million INR | -0.88% |
| 2021 | 695.54 Million INR | -5.62% |
| 2020 | 736.96 Million INR | 229.59% |
| 2019 | 223.6 Million INR | 9.03% |
| 2018 | 205.07 Million INR | 37.49% |
| 2017 | 149.16 Million INR | 43.71% |
| 2016 | 103.79 Million INR | 29.86% |
| 2015 | 79.92 Million INR | 16.62% |
| 2014 | 68.54 Million INR | -22.47% |
| 2013 | 88.4 Million INR | -50.37% |
| 2012 | 178.13 Million INR | -70.94% |
| 2011 | 612.89 Million INR | -20.33% |
| 2010 | 769.25 Million INR | 19.88% |
| 2009 | 641.67 Million INR | -18.13% |
| 2008 | 783.76 Million INR | -2.24% |
| 2007 | 801.73 Million INR | 41.26% |
| 2006 | 567.55 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 643.88 Million INR | -6.6% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 703.29 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 643.88 Million INR | 0.0% |
| 2022 Q4 | 689.41 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 641.21 Million INR | 0.0% |
| 2022 FY | 689.41 Million INR | -0.88% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 695.54 Million INR | -5.62% |
| 2021 Q4 | 695.54 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 717 Million INR | 0.0% |
| 2020 Q4 | 736.96 Million INR | 0.0% |
| 2020 FY | 736.96 Million INR | 229.59% |
| 2020 Q2 | 601.52 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 FY | 223.6 Million INR | 9.03% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 254.43 Million INR | 0.0% |
| 2019 Q4 | 223.6 Million INR | 0.0% |
| 2018 FY | 205.07 Million INR | 37.49% |
| 2018 Q4 | 205.07 Million INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 149.16 Million INR | 43.71% |
| 2016 FY | 103.79 Million INR | 29.86% |
| 2015 FY | 79.92 Million INR | 16.62% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q4 | 68.53 Million INR | 0.0% |
| 2014 Q2 | 67.55 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 68.54 Million INR | -22.47% |
| 2013 FY | 88.4 Million INR | -50.37% |
| 2013 Q2 | 325.36 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 86.9 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 465.3 Million INR | 0.0% |
| 2012 Q4 | 178.13 Million INR | 0.0% |
| 2012 FY | 178.13 Million INR | -70.94% |
| 2011 FY | 612.89 Million INR | -20.33% |
| 2010 FY | 769.25 Million INR | 19.88% |
| 2009 FY | 641.67 Million INR | -18.13% |
| 2008 FY | 783.76 Million INR | -2.24% |
| 2007 FY | 801.73 Million INR | 41.26% |
| 2006 FY | 567.55 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 62.612% |
| Aarti Drugs Limited | 11.5 Billion INR | 94.403% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 92.196% |
| Ajanta Pharma Limited | 10.71 Billion INR | 93.988% |
| Alembic Limited | 1.43 Billion INR | 55.039% |
| Alkem Laboratories Limited | 48.6 Billion INR | 98.675% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 96.043% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 82.413% |
| Bal Pharma Limited | 2.51 Billion INR | 74.36% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -122.952% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | 69.468% |
| Brooks Laboratories Limited | 248.6 Million INR | -159.003% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | 1.287% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 81.633% |
| Divi's Laboratories Limited | 18.99 Billion INR | 96.609% |
| Eris Lifesciences Limited | 38.26 Billion INR | 98.317% |
| Granules India Limited | 22.95 Billion INR | 97.195% |
| Ind-Swift Limited | 13.45 Billion INR | 95.214% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -116.971% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 93.987% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 98.949% |
| Medicamen Biotech Limited | 940.36 Million INR | 31.529% |
| Medico Remedies Limited | 438.24 Million INR | -46.923% |
| Wockhardt Limited | 39.87 Billion INR | 98.385% |
| Orchid Pharma Limited | 3.84 Billion INR | 83.25% |
| RPG Life Sciences Limited | 1.38 Billion INR | 53.349% |
| Shilpa Medicare Limited | 12.93 Billion INR | 95.021% |
| Sigachi Industries Limited | 2.53 Billion INR | 74.563% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 95.431% |
| Unichem Laboratories Limited | 8.06 Billion INR | 92.021% |
| Vaishali Pharma Limited | 371.16 Million INR | -73.477% |
| Wanbury Limited | 3.15 Billion INR | 79.595% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 99.103% |
| FDC Limited | 3.7 Billion INR | 82.641% |
| Amrutanjan Health Care Limited | 783.82 Million INR | 17.854% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 86.772% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.398% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 87.572% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | 71.876% |
| Laurus Labs Limited | 42.71 Billion INR | 98.493% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | 67.42% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 94.26% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -302.953% |
| Hester Biosciences Limited | 3.59 Billion INR | 82.088% |
| Ipca Laboratories Limited | 33.74 Billion INR | 98.092% |
| Venus Remedies Limited | 1.39 Billion INR | 53.771% |
| ZIM Laboratories Limited | 2.08 Billion INR | 69.055% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 99.577% |
| Morepen Laboratories Limited | 4.45 Billion INR | 85.562% |
| Neuland Laboratories Limited | 5.49 Billion INR | 88.29% |
| Sequent Scientific Limited | 8.27 Billion INR | 92.218% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | 68.348% |
| Valiant Laboratories Limited | 1.05 Billion INR | 39.157% |
| Windlas Biotech Limited | 1.76 Billion INR | 63.472% |
| Hikal Limited | 12.99 Billion INR | 95.045% |
| Innova Captab Limited | 4.89 Billion INR | 86.859% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 74.86% |
| Themis Medicare Limited | 1.88 Billion INR | 65.887% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 89.826% |
| Mankind Pharma Limited | 23.87 Billion INR | 97.303% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 99.011% |
| Sakar Healthcare Limited | 1.26 Billion INR | 49.031% |
| Albert David Limited | 1.15 Billion INR | 44.015% |
| Lupin Limited | 96.23 Billion INR | 99.331% |
| Gufic Biosciences Limited | 5.59 Billion INR | 88.502% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.649% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 40.079% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | 44.741% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.885% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.215% |
| NATCO Pharma Limited | 10.53 Billion INR | 93.886% |
| Suven Life Sciences Limited | 148.62 Million INR | -333.238% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 78.349% |
| Strides Pharma Science Limited | 37.68 Billion INR | 98.291% |
| Indoco Remedies Limited | 10.34 Billion INR | 93.774% |
| Alpa Laboratories Limited | 307.12 Million INR | -109.651% |
| Lasa Supergenerics Limited | 541.92 Million INR | -18.814% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 83.46% |